Can Schrödinger (SDGR) Stock Reach $40?

Key Takeaways

• Schrödinger (SDGR) closed near $29.45 after a powerful rally that took shares roughly 140% higher over six months and pushed the stock to fresh 52-week highs.
• The $40 stock price target represents a meaningful move of roughly 35% above recent levels and sits well above the stock's current 52-week high near $31.59.
• The strongest bullish drivers are accelerating annual contract value (ACV) growth, a surprising return to quarterly profitability, and expanding partnerships with major pharmaceutical companies.
• The biggest obstacles are a stretched valuation relative to consensus analyst price targets — most of which sit below the current share price — and a drug-discovery pipeline still in early clinical stages.
• Key levels to watch: the $31.59 52-week high as near-term resistance, with psychological support in the low-to-mid $20s.
• Investors should view $40 as an ambitious but not impossible target that depends on continued software momentum and favorable pipeline news.

Why Investors Are Watching $40

Schrödinger, Inc. (SDGR) is a physics-based computational drug-discovery company that blends a high-margin software business with a clinical-stage therapeutics pipeline. After spending much of 2024 and 2025 near its lows, the stock has staged a dramatic recovery, rallying from a 52-week low of roughly $10.94 to a recent high above $30. That rebound has naturally raised the question of how far the run can extend — and the round-number $40 level has become a focal point for investors searching for the next realistic milestone.

Company Overview and Market Position

Schrödinger operates through two reportable segments. Its Software segment licenses a proprietary computational platform used by biopharmaceutical, materials-science, and academic customers to design molecules more efficiently. Its Drug Discovery segment advances a portfolio of proprietary and partnered programs. The company reported full-year 2025 revenue of approximately $255.9 million, up 23% year over year, while its net loss narrowed by 45% to about $103.3 million.

What Could Drive the Next Leg Higher

The most compelling argument for a move toward $40 is improving operating momentum. In its most recent quarter, Schrödinger delivered a surprise profit — earnings per share (EPS) of $0.08 versus an expected loss — on revenue that beat forecasts by a wide margin. ACV, a key measure of recurring software growth, climbed 27% year over year, and hosted software revenue reached nearly half of total software revenue, up sharply from the prior year. Management has also guided to continued ACV expansion of roughly 10% to 15%.

Strategic partnerships reinforce the growth story. Schrödinger has expanded relationships with major pharmaceutical partners, including collaborations tied to its Bunsen AI co-scientist platform and enterprise informatics tools, and it co-founded a new biotechnology company, Tectora Therapeutics, alongside venture investors RA Capital and New Enterprise Associates. In the clinic, its MALT1 inhibitor SGR-1505 received Fast Track designation from the U.S. Food and Drug Administration (FDA), a signal of interest in the program's potential.

What Could Prevent the Move

Valuation is the most significant obstacle. Because the stock has run so far so fast, it now trades above the average analyst price target, which sits near $21, with the highest published target around $30. In other words, to reach $40, shares would need to rally roughly a third beyond even the most bullish published analyst target — a move that would likely require a fundamental re-rating rather than a simple continuation of momentum.

The company also remains loss-making on a consolidated basis, with a negative net margin and continued investment in research and development. Its proprietary drug pipeline is still early-stage, and clinical programs carry binary risk: Schrödinger already discontinued its SGR-2921 CDC7 inhibitor program in 2025, a reminder that individual assets can fail. With a beta of roughly 1.69, the stock is also notably more volatile than the broader market, making sharp pullbacks a recurring risk after such a rapid advance.

Technical Levels That Matter

From a technical-analysis standpoint, the most important level is the 52-week high near $31.59. A decisive break and hold above that zone would confirm the longer-term uptrend and open the door to higher prices. On the downside, the low-to-mid $20s represent a logical support area where recent consolidation occurred, and the stock's long journey from under $11 leaves ample room for profit-taking. The $40 target functions as a psychological milestone sitting well above the prior high, meaning it would require genuine new demand rather than a simple retest of old levels.

AI Daily Buy/Sell Signals

For traders looking to track momentum in names like Schrödinger, Tickeron's AI Daily Buy/Sell Signals offer a data-driven way to monitor shifting conditions. The product uses artificial intelligence to continuously analyze thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market behavior, technical patterns, and AI-driven analysis. These signals can help traders surface new opportunities, keep an eye on existing positions, and identify changing market trends more efficiently than manual screening alone.

Final Assessment

A move to $40 for Schrödinger is ambitious but not out of reach over a longer horizon. The strongest support comes from accelerating software ACV, a surprise return to quarterly profitability, and a string of high-profile partnerships that validate the platform's commercial relevance. However, the primary risks are significant: the stock already trades above the consensus analyst price target, the company remains unprofitable on a full-year basis, and its clinical pipeline is still early and inherently uncertain. Investors should monitor software ACV growth, hosted-software adoption, pipeline data readouts, and whether shares can hold above their prior highs before assuming a sustained push toward $40.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations